Depression during pregnancy and in the postpartum period is common, devastating to mothers and their offspring, and poorly understood in terms of pathophysiology. In this issue of Neuron, Maguire and Mody provide evidence for a role for aberrant neurosteroid regulation of the GABA A receptor subunit in the etiology of postpartum depression, presaging elucidation of the pathophysiology and development of treatments of this depression endophenotype.
There is increasing attention in all branches of medicine to elucidation of pathophysiologically distinct subtypes of syndromes ranging from diabetes and cardiomyopathies to cerebrovascular accidents (stroke) and mood disorders (Craddock et al., 2008) . Elucidation of such endophenotypes is essential to identify their unique pathophysiology and thereby develop novel treatment strategies. At the present time, patients who fulfill criteria for major depression are generally treated by a trial and error method with psychotherapy or antidepressants (or both) previously shown to be effective, irrespective of the depressive subtype. Currently, with a few exceptions such as depression with psychotic features (Nemeroff, 2006) , there is insufficient data to drive clinical decision-making as to which particular antidepressant, mood stabilizer, or psychotherapeutic method is best suited for any depressive subtype, much less for any individual patient. This likely explains why largescale clinical trials have revealed remission rates in the acute treatment of major depression of approximately 28%-40% (Nemeroff et al., 2008) , which are clearly less than optimal.
Although there is considerable evidence for a preeminent role for three monoamine systems, serotonin (5HT), norepinephrine (NE), and dopamine (DA), in the pathogenesis of depression, depression clearly involves other circuits including neuropeptide systems such as corticotropin-releasing factor (CRF) and glutamate and GABA circuits (Ressler and Nemeroff, 2007; Kasa et al., 1982) .
Depression during pregnancy and in the postpartum period is an area of much needed research, in terms of both pathophysiology and treatment. Women are more than twice as susceptible to depression as men (Kessler et al., 2005) , and in spite of the popular notion that pregnancy protects against depression, it does not. Rates of depression during pregnancy are not lower than in the nonpregnant state, approximately 14%-20% (Oberlander et al., 2006) , and postpartum depression defined as depression within one year of delivery is very common, affecting 10%-22% of adult women, with higher rates in adolescent women (Kendler et al., 1993) . It is important to note that there is increasing evidence that depression during pregnancy and in the postpartum period has adverse effects, both physiological and behavioral, on their offspring (Gluckman et al., 2008) . Because of the concerns of women and their healthcare providers about the potential adverse effects of psychotropic medications on the fetus and newborn (via breastfeeding) if prescribed during pregnancy or during the postpartum period, respectively, the calculation of risk-benefit ratios is of paramount importance. In essence, depriving women during pregnancy and in the puerperium from psychopharmacological treatment for mood disorders increases the risk of suicide, infanticide, drug and alcohol abuse, and malnutrition (Stowe and Nemeroff, 1995) , as well as disrupts the mother-infant relationship during a critical period in child development. However, treatment of women during pregnancy or in the postpartum period exposes their offspring to psychotropic medication which may have adverse side effects.
One major impediment to advances in mood disorders research has been a relative lack of animal models of depression, as opposed, for example, to animal models of anxiety disorders (Arborelius and Nemeroff, 2002) or substance abuse (Koob and Le Moal, 2006) . Moreover, it is well established that, on average, the risk for the development of major depression is approximately one-third genetic and two-thirds environmental. Major advances in basic research in genetics and molecular neurobiology have, of course, largely utilized mice, whereas the vast majority of animal models of psychiatric disorders have, in contrast, utilized rats. The report in this issue of Neuron by Maguire and Mody (2008) on GABA A receptor (GABA A R) plasticity during pregnancy and its implications for the pathophysiology of postpartum depression likely represents an incremental breakthrough in the field. They demonstrate that in mice GABA A R expression is markedly downregulated by the increase in progesteronederived neurosteroids during pregnancy, an effect which rebounds rapidly in the postpartum period. After demonstrating reductions in GABA A R subunit expression in the hippocampus in mice during pregnancy and the functional consequences by whole-cell patch-clamp recordings, studies were conducted in mice that do not exhibit GABA A R subunit regulation (Gabrd +/À and Gabrd In addition, and uncannily relevant to the small but significant increase in infanticide in women with postpartum depression, was a significant increase in pup mortality in the GABA A R d subunit knockout mice due to maternal neglect and cannibalism. Most impressive is the reversal of these behavioral alterations by treatment with the GABA A R d-subunit-selective agonist THIP. The implications of this research are considerable and it suggests several future research directions. Functional brain imaging studies could elucidate GABA and GABA A R alterations in depressed women during pregnancy or postpartum using magnetic resonance spectroscopy (MRS) and PET imaging, respectively. Genetic studies can determine if genetic polymorphisms of the GABA A R or other components of the GABA system predict vulnerability to postpartum depression. Finally, treatment studies with THIP or related molecules in postpartum depression would surely be of interest.
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Correct wiring of brain circuitry during development involves the selective formation and retention of synaptic connections between neurons. In this issue of Neuron, Lohmann and Bonhoeffer show that dendritic filopodia can distinguish among prospective presynaptic axonal targets during development. Contact with the appropriate target triggers local calcium signals that stabilize the filopodia and tell them to form mature synapses.
It has long been known that synapse formation involves movement of both future presynaptic axons and postsynaptic dendrites, particularly movement of dendritic filopodia (Ziv and Smith, 1996; Jontes and Smith, 2000; Lohmann et al., 2002) . This reciprocal movement leads to physical contact between the two cells, which can yield mature synaptic connections if these contacts are stabilized and subsequently converted into synaptic structures. It is not known how, during this developmental dance, the correct targets are identified among many other neighboring cells that potentially could serve as alternative targets. The paper by Christian Lohmann and Tobias Bonhoeffer in this issue of Neuron (Lohmann and Bonhoeffer, 2008) provides new insights into how targets are identified and how synaptic contacts between these cells are subsequently stabilized.
The experiments described in this paper used dynamic fluorescent imaging of multiple neurons in cultured hippocampal slices to watch how dendritic filopodia form contacts with axons. Presynaptic axons were labeled by a green calcium indicator dye or by GFP-labeled GAD65 or synaptophysin, while individual
